drug · small molecule

COMBIGAN

updated 3mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 9 investigational indications.

targets

Adrenergic receptor alpha-2

all catalysts(0)

nothing on the calendar yet

Trials studying COMBIGAN

phase2A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expressionrecruitingn=100
phase3Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solutioncompletedn=512
phase3Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitiscompletedn=229
phase4Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensivecompletedn=60
phase3Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitiscompletedn=188
phase2TAR-0520 Gel in EGFR Inhibitor-induced Folliculitisrecruitingn=60
phase3"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"completedn=380
phase3BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertensioncompletedn=406

more trials →

News(0)

no news has mentioned this drug yet

brand

COMBIGAN

trade names

Alphagan, Alphagan p, Brimonidine tartrate, Brimonidine tartrate component of combigan, Brimonidine tartrate component of simbrinza, Brymont

generic

BRIMONIDINE TARTRATE

MOA

12.1 Mechanism of Action COMBIGAN is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage. COMBIGAN is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Timolol maleate is a beta 1 and beta 2 adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.

indication

1 INDICATIONS AND USAGE COMBIGAN ® is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The IOP-lowering of COMBIGAN dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. COMBIGAN is a combination of brimonidine tartrate, an alpha-adrenergic receptor agonist, and timolol maleate, a beta-adrenergic receptor inhibitor, indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The IOP-lowering of COMBIGAN dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate ophthalmic solution, 0.5% dosed twice a day and brimonidine tartrate ophthalmic solution, 0.2% dosed three times per day. ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 5m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

COMBIGAN

updated 3mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 9 investigational indications.

targets

Adrenergic receptor alpha-2

all catalysts(0)

nothing on the calendar yet

Trials studying COMBIGAN

phase2A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expressionrecruitingn=100
phase3Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solutioncompletedn=512
phase3Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitiscompletedn=229
phase4Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensivecompletedn=60
phase3Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitiscompletedn=188
phase2TAR-0520 Gel in EGFR Inhibitor-induced Folliculitisrecruitingn=60
phase3"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"completedn=380
phase3BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertensioncompletedn=406

more trials →

News(0)

no news has mentioned this drug yet

brand

COMBIGAN

trade names

Alphagan, Alphagan p, Brimonidine tartrate, Brimonidine tartrate component of combigan, Brimonidine tartrate component of simbrinza, Brymont

generic

BRIMONIDINE TARTRATE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 5m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

COMBIGAN

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying COMBIGAN

News(0)

Report a data issue

comments(0)

COMBIGAN

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying COMBIGAN

News(0)

Report a data issue

comments(0)